Gallant's Feline OA Stem Cell Therapy Posts Positive Pilot Data, Wins FDA Fast-Track Eligibility

Gallant, the San Diego-based animal health biotech, reported positive results from a pilot clinical study of its IV stem cell therapy for feline osteoarthritis and received FDA eligibility for the expanded conditional approval pathway. With OA affecting up to 90% of older cats and Zoetis dominating the category with monthly and quarterly mAb injections, Gallant is bringing an entirely different treatment modality to the table: regenerative medicine that could offer lasting relief rather than recurring symptom management.

What Happened

Gallant announced on April 15 that its intravenous uterine-derived mesenchymal stromal cell (UMSC) therapy showed positive results in a pilot study of cats with naturally occurring osteoarthritis. The FDA's Center for Veterinary Medicine granted eligibility for the expanded conditional approval pathway, a faster route to market designed for products addressing significant unmet medical needs.

This is Gallant's second FDA milestone in recent months. Its lead product, sonruvetcel suspension for injection targeting refractory feline chronic gingivostomatitis (FCGS), previously achieved FDA "technical section complete" for Reasonable Expectation of Effectiveness and is on track for conditional approval. In that FCGS program, two-thirds of cats showed a positive response one year post-treatment.

Gallant has raised $61.5 million across four rounds, most recently an $18 million Series B in June 2025 led by Digitalis Ventures with participation from BOLD Capital, Hill Creek Partners, and NovaQuest Capital Management. The company is led by CEO Dr. Linda Black, who took the helm after co-founder Aaron Hirschhorn died in a boating accident in 2021. Gallant's platform develops standardized, off-the-shelf (allogeneic) stem cell therapies, meaning the cells come from donor animals rather than the patient, eliminating the need for individual cell banking and making the therapy scalable.

Why It Matters

1. This opens a third front in the feline OA treatment landscape. Zoetis currently owns feline OA pain management with Solensia (monthly mAb injection) and the soon-to-launch Portela (quarterly mAb injection). Both are symptom management therapies requiring ongoing treatment. Gallant's stem cell approach is fundamentally different: regenerative medicine that aims to repair damaged tissue rather than mask pain signals. If the data holds through larger trials, vet clinics could eventually offer cat owners a choice between recurring injections and a potentially longer-lasting regenerative treatment. That's a formulary decision that didn't exist a year ago.

2. The expanded conditional approval pathway matters for timeline. Traditional FDA approval in veterinary medicine can take years. The expanded conditional approval pathway allows products to reach the market while full effectiveness data is still being collected, provided safety and manufacturing standards are met. For Gallant, this could mean a feline OA product available to clinics well before a full pivotal trial is complete. For clinic operators, it means planning for a new treatment option that could arrive faster than expected.

3. The allogeneic model is the business innovation. Stem cell therapies in veterinary medicine aren't new, but most require harvesting cells from the individual patient, processing them, and re-injecting. That's expensive, logistically complex, and difficult to scale. Gallant's off-the-shelf approach uses donor-derived cells that can be manufactured, standardized, and shipped like any other pharmaceutical product. If approved, this makes stem cell therapy accessible to any general practice, not just specialty referral hospitals with cell processing capabilities.

4. The timing alongside Zoetis's Citi catalyst watch is no coincidence. On the same day Citi named Zoetis its top pick in animal health and opened a 90-day catalyst watch on Solensia's recovery, Gallant dropped positive OA data and an FDA pathway milestone. The feline OA market is heating up, and the competitive dynamic between established pharma (Zoetis's mAb portfolio) and biotech challengers (Gallant's regenerative approach) will shape treatment protocols and clinic revenue models for years.

5. Follow the investor profile. NovaQuest Capital Management, which participated in the Series B, specializes in life sciences royalty and milestone-based investments. Their involvement suggests a revenue-generating product is within a commercial timeline that institutional investors find credible, not a 10-year science project.

What to Watch

FCGS conditional approval: Gallant's gingivostomatitis product is closest to market. If it becomes the first FDA-labeled allogeneic stem cell therapy in veterinary medicine, it validates the entire platform and de-risks the OA program. Watch for a conditional approval announcement in 2026.

Pivotal trial design for feline OA: The pilot data is encouraging but small-scale. The size, endpoints, and timeline of a larger confirmatory study will determine how quickly Gallant can move toward conditional approval for OA specifically.

Pricing and positioning: Stem cell therapies in veterinary medicine typically command premium pricing ($1,000-$3,000+ per treatment for autologous procedures). An off-the-shelf product should be significantly cheaper, but where Gallant prices relative to Solensia (~$80-100/month) and Portela (quarterly pricing TBD) will determine its market positioning. If priced as a premium one-time treatment vs. ongoing monthly/quarterly spend, the lifetime value calculation becomes interesting for both pet owners and clinics.

Zoetis's response: The largest animal health company in the world is not going to cede the feline OA market to a biotech with $61.5 million in funding. Watch for Zoetis to either accelerate its own regenerative medicine pipeline, pursue strategic partnerships, or position Lenivia/Portela as complementary rather than competitive with stem cell approaches.

Source: Gallant via PR Newswire · Gallant Series B via PR Newswire